Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Acknowledgments NA gratefully acknowledges the partial financial supports received from FCT (Government of Portugal) through contract (SFRH/BPD/84671/2012), the Aveiro University Research Institute/CESAM (UID/AMB/50017/2013), COMPETE through Project n. FCOMP-01-0124-FEDER-02800 (FCT PTDC/AGR-PRO/4091/2012), and to FCT/MEC through national funds, and the co-funding by the FEDER, within the PT2020 Partnership Agreement and Compete 2020
BPC-157 was prohibited under WADA's S0 Unapproved Substances category in 2022, restricting use in competition and training
Use in any patient with an active or recent malignancy
10.1039/d4ra02336f 59 LiC.CuiK.ZhuX.WangS.YangQ.FangG
Prescribing unapproved drugs is not routine medical practice Without FDA approval or an authorized investigational pathway, licensed providers do not have authority to prescribe experimental compounds as treatment
every 1-3 months) is recommended to ensure the optimal dose is achieved to reach the desired therapeutic outcome
US$ 26.65
US$ 21.57
US$ 24.31
US$ 28.39
US$ 27.40
.webp)
US$ 22.30
